Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genmab A/S ADR (NQ: GMAB )

20.89 +0.24 (+1.14%)
Streaming Delayed Price Updated: 10:32 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S ADR

< Previous 1 2 3 4 5 6 7 8 Next >
AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial
Via Benzinga
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium
From Genmab
Via Business Wire
Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
From Seagen Inc.
Via Business Wire
Analyst Ratings for Genmab
Within the last quarter, Genmab (NASDAQ:GMAB) has observed the following analyst ratings: 
Via Benzinga
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
From Genmab A/S
Via Business Wire
Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Genmab
Via Business Wire
Johnson & Johnson Stock: A Rare Bright Spot in the Market
JNJ stock is up on the year thanks in part to its steadily rising dividend, which investors covet during the current market volatility. 
Via InvestorPlace
Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress
From Genmab
Via Business Wire
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study
Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV) 
Via Benzinga
Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
From Genmab A/S
Via Business Wire
BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties
Via Benzinga
Best Biotech Stocks To Buy In 2022
Biotechnology is the study of living creatures, biological systems, or derivatives to develop or improve healthcare products and therapies. This technology is connected with medical and... 
Via Talk Markets
Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
From Seagen Inc.
Via Business Wire
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
From Genmab A/S
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago... 
Via Benzinga
A Bearish Sign Looms Over Genmab's Chart
If history is any guide, there may be trouble ahead for shares of Genmab (NASDAQ:GMAB). A so-called "death cross" has formed on its chart and, not surprisingly, this... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 3, 2022
Upgrades For nVent Electric PLC (NYSE:NVT), Vertica... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2021
Upgrades Goldman Sachs upgraded the previous rating for Grupo Aeroportuario del Sureste SAB de CV 
Via Benzinga
Genmab A/S (GMAB) Q3 2021 Earnings Call Transcript
GMAB earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To... 
Via Benzinga
Exposures COVID-19 Product Safety
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)
From Genmab A/S
Via Business Wire
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
From Genmab
Via Business Wire
Why Genmab's Stock Is Trading Higher Today
Genmab A/S (NASDAQ:GMAB) shares are trading higher after the company, along with Seagen Inc. (NASDAQ: SGEN), announced the FDA has granted accelerated approval to... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.